The main complaints were pain in both ears, diplopia, and restriction of inward movement of the left eye after the CHOP (Cyclophosphamide, Hydroxydaunorubicin, Oncovin
, and Prednisone) treatment.
5 FOLFOX 0 IAP 0 ABVD: Adriamycin, bleomycin, vinblastine, dacarbazine, ICE: Ifosfamide, carboplatin, etoposide, ECF: Epirubicin, cisplatin, 5-fluorouracil, FEC: 5-fluorouracil, epirubicin, cyclophosphamide, IA: Idarubicin, Cytarabine, CHOP: Cyclophosphamide, hydroxyl-daunorubicin, oncovin
, prednisone, FOLFOX: Fluorouracil, leucovorin, oxaliplatin, IAP: Oxaliplatin, epirubicin, ifosfamide Table 3: Adverse effects in study subjects Adverse n (%) effects Interventional group Non-interventional group Nausea 0 1 (5) Diarrhea 3 (15) 4 (20) Dizziness 2 (10) 1 (5) Vomiting 3 (15) 5 (25) Headache 2 (10) 2 (10) Dysgeusia 4 (20) 2 (10)
sup] Second, ABVD has been widely used in clinical practice as a more effective treatment regimen over mechlorethamine, Oncovin
(vincristine), procarbazine, and prednisone.
marneffei Antifungal treatment Amphotericin B (2 (duration, mo) weeks) and voriconazole (>5) Other opportunistic Herpes zoster infections at right occiput Clinical outcome Responded to antifungal treatment * mAb, monoclonal antibody; JAK, Janus kinase; IV, intravenous; CHOP, cyclophosphamide, hydroxydaunorubicin, oncovin
, and prednisolone; MRCNS, methicillin-resistant coagulase-negative Staphylococcus; HSV, herpes simplex virus; PJP, Pneumocystis jiroveci pneumonia; MODS, multiple organ dysfunction syndrome.
Diffuse large B-cell lymphoma with c-MYC detected by IHC showed adverse prognosis and inferior overall survival when treated with rituximab with cyclophosphamide, hydroxydaunorubicin, Oncovin
(vincristine), and prednisone (R-CHOP).
1 However standard modality has been chemotherapy and the regimen includes cyclophosphamide, doxorubicin, oncovin
(vincristine), which prevents cells from duplicating by binding to the protein tubulin
2] adriamycin and l-2 mg oncovin
intravenously infused on day 1; and 40 mg prednisone taken orally on days 1-5, with an interval of 3 weeks between two courses of treatment).
Five of the patients who were diagnosed as Hodgkin lymphoma were treated with adriablastine, belomycine, vinblastine, dacabazine, six were treated with cyclophosphamide, oncovin
, procarbazine and prednisolone and six were treated with successive adriablastine, bleomycine, vinblastin, dacarbazine-cyclophosphmide, vincristin, procarbazine and prednisolone.
Non-toxic sensitization of cancer chemotherapy by combined vitamin C and K3 pretreatment in a mouse tumor resistant to Oncovin